460 related articles for article (PubMed ID: 34788184)
21. Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies.
Marelli L; Stigliano R; Triantos C; Senzolo M; Cholongitas E; Davies N; Yu D; Meyer T; Patch DW; Burroughs AK
Cancer Treat Rev; 2006 Dec; 32(8):594-606. PubMed ID: 17045407
[TBL] [Abstract][Full Text] [Related]
22. Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial.
Seinstra BA; Defreyne L; Lambert B; Lam MG; Verkooijen HM; van Erpecum KJ; van Hoek B; van Erkel AR; Coenraad MJ; Al Younis I; van Vlierberghe H; van den Bosch MA
Trials; 2012 Aug; 13():144. PubMed ID: 22913492
[TBL] [Abstract][Full Text] [Related]
23. Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis.
Zhang L; Hu P; Chen X; Bie P
PLoS One; 2014; 9(6):e100305. PubMed ID: 24945380
[TBL] [Abstract][Full Text] [Related]
24. Medical Treatment for Hepatocellular Carcinoma in Japan.
Kawano Y; Kaneya Y; Aoki Y; Yoshioka M; Matsushita A; Shimizu T; Ueda J; Takata H; Taniai N; Kanda T; Hirakata A; Suzuki H; Yoshida H
J Nippon Med Sch; 2022 May; 89(2):154-160. PubMed ID: 35082203
[TBL] [Abstract][Full Text] [Related]
25. High rate of complete histopathological response in hepatocellular carcinoma patients after combined transarterial chemoembolization and stereotactic body radiation therapy.
Bauer U; Gerum S; Roeder F; Münch S; Combs SE; Philipp AB; De Toni EN; Kirstein MM; Vogel A; Mogler C; Haller B; Neumann J; Braren RF; Makowski MR; Paprottka P; Guba M; Geisler F; Schmid RM; Umgelter A; Ehmer U
World J Gastroenterol; 2021 Jun; 27(24):3630-3642. PubMed ID: 34239274
[TBL] [Abstract][Full Text] [Related]
26. Transarterial chemoembolization (TACE) for unresectable HCC: a new life begins?
Biolato M; Marrone G; Racco S; Di Stasi C; Miele L; Gasbarrini G; Landolfi R; Grieco A
Eur Rev Med Pharmacol Sci; 2010 Apr; 14(4):356-62. PubMed ID: 20496548
[TBL] [Abstract][Full Text] [Related]
27. Experience from a real-life cohort: outcome of 606 patients with hepatocellular carcinoma following transarterial chemoembolization.
Kirstein MM; Schweitzer N; Ay N; Boeck C; Lappas K; Hinrichs JB; Voigtländer T; Wacker F; Manns MP; Rodt T; Vogel A
Scand J Gastroenterol; 2017 Jan; 52(1):116-124. PubMed ID: 27598949
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic advances for patients with intermediate hepatocellular carcinoma.
Sun JY; Yin T; Zhang XY; Lu XJ
J Cell Physiol; 2019 Aug; 234(8):12116-12121. PubMed ID: 30648254
[TBL] [Abstract][Full Text] [Related]
29. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma.
Llovet JM; De Baere T; Kulik L; Haber PK; Greten TF; Meyer T; Lencioni R
Nat Rev Gastroenterol Hepatol; 2021 May; 18(5):293-313. PubMed ID: 33510460
[TBL] [Abstract][Full Text] [Related]
30. Transarterial chemoembolization combined with microwave ablation and apatinib in patients with Barcelona clinic liver cancer Stage C hepatocellular carcinoma: A propensity score matching analysis.
Shuanggang C; Shen L; Qiu Z; Qi H; Cao F; Xie L; Fan W
J Cancer Res Ther; 2020; 16(2):250-257. PubMed ID: 32474509
[TBL] [Abstract][Full Text] [Related]
31. Combined radiofrequency ablation or microwave ablation with transarterial chemoembolization can increase efficiency in intermediate-stage hepatocellular carcinoma without more complication: a systematic review and meta-analysis.
Yang Y; Yu H; Qi L; Liu C; Feng Y; Qi J; Li J; Zhu Q
Int J Hyperthermia; 2022; 39(1):455-465. PubMed ID: 35271786
[TBL] [Abstract][Full Text] [Related]
32. Prognosis of patients with hepatocellular carcinoma and portal vein tumor thrombus treated with combination of transarterial chemoembolization and palliative thermal ablation.
Zhou Q; An Y; Liu T; Liu Z; Li R; Wang C; Zhou F; Liu C; Zhu K
Int J Hyperthermia; 2022; 39(1):97-107. PubMed ID: 34979845
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of Adding Locoregional Therapy in Non-Complete Remission Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab: A Preliminary Study.
Ishikawa T; Yamazaki S; Sato R; Jimbo R; Kobayashi Y; Sato T; Iwanaga A; Sano T; Yokoyama J; Honma T
Anticancer Res; 2024 Jan; 44(1):361-368. PubMed ID: 38159993
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial.
Yoon SM; Ryoo BY; Lee SJ; Kim JH; Shin JH; An JH; Lee HC; Lim YS
JAMA Oncol; 2018 May; 4(5):661-669. PubMed ID: 29543938
[TBL] [Abstract][Full Text] [Related]
35. Comparison of Transarterial Chemoembolization Combined with Radiofrequency Ablation Therapy
Yi PS; Huang M; Zhang M; Xu L; Xu MQ
Am Surg; 2018 Feb; 84(2):282-288. PubMed ID: 29580359
[TBL] [Abstract][Full Text] [Related]
36. Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma.
Ni JY; Liu SS; Xu LF; Sun HL; Chen YT
World J Gastroenterol; 2013 Jun; 19(24):3872-82. PubMed ID: 23840128
[TBL] [Abstract][Full Text] [Related]
37. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
[TBL] [Abstract][Full Text] [Related]
38. Aggressive intrahepatic therapies for synchronous hepatocellular carcinoma with pulmonary metastasis.
Hu Z; Huang P; Zhou Z; Li W; Xu J; Xu K; Wang J; Zhang H
Clin Transl Oncol; 2018 Jun; 20(6):729-739. PubMed ID: 29110217
[TBL] [Abstract][Full Text] [Related]
39. [Transarterial ablative therapy of hepatocellular carcinoma].
Mahnken AH
Radiologe; 2014 Jul; 54(7):685-93. PubMed ID: 25047524
[TBL] [Abstract][Full Text] [Related]
40. Interventional treatment for unresectable hepatocellular carcinoma.
Murata S; Mine T; Sugihara F; Yasui D; Yamaguchi H; Ueda T; Onozawa S; Kumita S
World J Gastroenterol; 2014 Oct; 20(37):13453-65. PubMed ID: 25309076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
